TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02406027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 10 mg
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 10 mg
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 25 mg
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 25 mg
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self administer placebo matching to JNJ-54861911 orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-54861911, 5 mg
Description: Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
Study: NCT00775801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLD
Description: Artificial lumbar disc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Artificial lumbar disc
Study: NCT00789373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
Study: NCT02085629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor M reg (Mreg_UKR)
Description: Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description).
Study: NCT03412734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine preparation solutions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Iodine-based preparation solutions
Study: NCT01534039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sur-Fit Natura
Description: ConvaTec Moldable Skin Barrier for ostomy patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FormaFlex
Description: Hollister skin barrier for ostomy patients
Study: NCT00927862

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: IWPC adapted genotype-guided dosing algorithm for warfarin
Description: Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Modified IWPC genetic-guided warfarin dosing algorithm
Description: Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients \>=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
Study: NCT04042623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug
Study: NCT04152811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes
Description: Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes
Description: Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diabetes Care
Description: Usual Diabetes Care
Study: NCT04439526

Intervention type: DRUG
Intervention: Guselkumab
Description: Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.

Intervention type: DRUG
Intervention: Guselkumab
Description: Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
Study: NCT03314415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aldebaraan Nao H25
Description: The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aldebaraan Nao H25
Description: The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
Study: NCT03162224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0457
Description: MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0457
Description: MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0457
Description: MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®5P device
Description: MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®5P device
Description: MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®5P device
Description: MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
Study: NCT02216175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLIT to cow's milk
Description: Sublingual immunotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dose OIT
Description: Oral Immunotherapy (low dose)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OIT to cow's milk
Description: Oral Immunotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional OIT to cow's milk
Description: Oral Immunotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional OIT to cow's milk
Description: Oral Immunotherapy
Study: NCT04480853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg QD, oral
Study: NCT00676715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex
Description: Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
Study: NCT03905655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Number of placebo tablets administered orally depends on the arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Number of placebo tablets administered orally depends on the arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Number of placebo tablets administered orally depends on the arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
Study: NCT03468426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: intra-venous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: intra-venous infusion
Study: NCT02962687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management via videoconference
Description: 12-week nurse care management for medically complex Veterans with CI delivered via videoconference

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care management via telephone calls
Description: 12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
Study: NCT01008033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-108
Description: Topical application once a day for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application once a day for 48 weeks
Study: NCT03453398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shifts working hours with different schedules
Description: Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shifts working hours with different schedules
Description: Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shifts working hours with different schedules
Description: Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study.
Study: NCT00000392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptide T

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01796574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: 4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
Study: NCT03117738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AstroStem
Description: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: Saline with 30% auto-serum
Study: NCT01087853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: 2 litres intravenous infusion in 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: 2 litres intravenous infusion in 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: 1 litre intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: 1 litre intravenous infusion over 30 minutes
Study: NCT03149887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
Study: NCT03174470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Stimulator
Description: Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
Study: NCT04152811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diabetes Care
Description: Usual Diabetes Care
Study: NCT01090349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an ICD/CRT-D device
Description: The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an ICD/CRT-D device
Description: The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merlin.NET PCN
Description: The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merlin.NET PCN
Description: The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
Study: NCT01838564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Data collection
Description: Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST.
Study: NCT03494907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Seltorexant
Description: Participants will be administered matching placebo to seltorexant tablets on Day 1.
Study: NCT01838564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Data collection
Description: Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback of patient-reported outcomes
Description: Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
Study: NCT02400554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yappalli
Description: Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, \& women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership \& personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion \& synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal \& leadership goals \& experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD \& obesity prevention. Includes: digital storytelling training to create a story related to ATOD \& obesity prevention \& an individual MI booster session to revise their personal \& community leadership goals.~Month 12: Share digital stories \& community event experiences \& undergo a ceremony to transition to health leaders within their communities.
Study: NCT00513045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRT
Description: Cognitive behavior intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: Exposure intervention
Study: NCT04768413

Intervention type: OTHER
Intervention: Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis
Description: A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.

Intervention type: OTHER
Intervention: Care modalities. Quantitative and qualitative approaches to analysis
Description: Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.